RM Doses, Absolute and Normalized
| Patient no. | Pretreatment/predosing* | Activity in L2-L4 at 96 h (MBq) | Half-life, 2 time points (d) | Absorbed dose (cGy) | Dose/injected activity (mGy/MBq) |
| 1 | R | 4.8 | 3.1 | 158 | 1.4 |
| 13 | R | 9.2 | 1.9 (2.3) | 207 | 1.5 |
| 14 | R | 5.3 | 3.3 (4.3) | 184 | 1.8 |
| 15 | R | 10.1 | 3.0 | 159 | 1.4 |
| 2 | R + lilotomab | 2.3 | 6.4 | 67 | 0.6 |
| 3 | R + lilotomab | 2.5 | 4.8 | 89 | 1.2 |
| 9 | R + lilotomab | 4.4 | 4.4 | 116 | 0.7 |
| 12 | R + lilotomab | 3.4 | 2.5 | 127 | 1.2 |
↵* R refers to pretreatment with rituximab; lilotomab refers to predosing with unlabeled antibody.
Data in parentheses are half-life, 3 time points.